Apellis Piotroski F Score

APLS
 Stock
  

USD 50.96  0.84  1.68%   

This module uses fundamental data of Apellis Pharmaceuticals to approximate its Piotroski F score. Apellis Pharmaceuticals F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Apellis Pharmaceuticals. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Apellis Pharmaceuticals financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Please continue to Apellis Pharmaceuticals Altman Z Score, Apellis Pharmaceuticals Correlation, Apellis Pharmaceuticals Valuation, as well as analyze Apellis Pharmaceuticals Alpha and Beta and Apellis Pharmaceuticals Hype Analysis.
  
Apellis Pharmaceuticals Long Term Debt to Equity is relatively stable at the moment as compared to the past year. Apellis Pharmaceuticals reported last year Long Term Debt to Equity of 0.95. As of 11/30/2022, Debt to Equity Ratio is likely to grow to 1.11, while Total Debt is likely to drop slightly above 203.1 M. Apellis Pharmaceuticals Long Term Debt to Equity is relatively stable at the moment as compared to the past year. Apellis Pharmaceuticals reported last year Long Term Debt to Equity of 0.95. As of 11/30/2022, Quick Ratio is likely to grow to 7.82, while Total Assets Per Share are likely to drop 7.33.
At this time, it appears that Apellis Pharmaceuticals' Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
4.0
Piotroski F Score - Poor
1
Current Return On AssetsNegativeFocus
2
Change in Return on AssetsDecreasedFocus
3
Cash Flow Return on AssetsNegativeFocus
4
Current Quality of Earnings (accrual)ImprovingFocus
5
Asset Turnover GrowthIncreaseFocus
6
Current Ratio ChangeIncreaseFocus
7
Long Term Debt Over Assets ChangeLower LeverageFocus
8
Change In Outstending SharesIncreaseFocus
9
Change in Gross MarginNo ChangeFocus

Apellis Pharmaceuticals Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Apellis Pharmaceuticals is to make sure Apellis is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Apellis Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Apellis Pharmaceuticals' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted91.1 M84.4 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares91.1 M84.4 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities142.3 M131.8 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities737 M683.1 M
Significantly Up
Increasing
Slightly volatile
Gross Margin89.2189.73
Slightly Down
Decreasing
Slightly volatile
Total Debt203.1 M210.2 M
Sufficiently Down
Increasing
Slightly volatile
Asset Turnover0.07410.0723
Fairly Up
Decreasing
Slightly volatile
Current Assets889.1 M824 M
Significantly Up
Increasing
Slightly volatile
Total Assets951.4 M881.8 M
Significantly Up
Increasing
Slightly volatile

Apellis Pharmaceuticals F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Apellis Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Apellis Pharmaceuticals in a much-optimized way.

About Apellis Pharmaceuticals Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value per Share

2.93

Apellis Pharmaceuticals Book Value per Share is relatively stable at the moment as compared to the past year. Apellis Pharmaceuticals reported last year Book Value per Share of 2.35

Apellis Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Apellis Pharmaceuticals from analyzing Apellis Pharmaceuticals' financial statements. These drivers represent accounts that assess Apellis Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Apellis Pharmaceuticals' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(1.31 M)(1.47 M)(1.3 M)(919.6 K)(1.57 M)(1.69 M)
Average Assets104.78 M218.18 M372.66 M821.99 M729.37 M603.86 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(50.88 M)(127.3 M)(304.29 M)(316.62 M)(731.8 M)(751.06 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(50.63 M)(124.99 M)(298.83 M)(312.23 M)(731.27 M)(750.51 M)
Earnings before Tax(51.01 M)(127.5 M)(304.71 M)(343.03 M)(746 M)(765.63 M)
Average Equity86.37 M178.88 M139.41 M200.36 M12.88 M13.21 M
Free Cash Flow(46.6 M)(131.24 M)(212.83 M)(165.91 M)(564.23 M)(579.08 M)
Invested Capital26.32 M37.29 M128.54 M642.93 M318.38 M262.8 M
Invested Capital Average12.63 M31.44 M74.77 M631.45 M556.3 M600.22 M
Tangible Asset Value182.13 M203.53 M389.25 M960.57 M881.76 M951.38 M
Working Capital175.46 M185.41 M307.34 M788.87 M692.2 M546.92 M

About Apellis Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Apellis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apellis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apellis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 476 people.

Apellis Pharmaceuticals Investors Sentiment

The influence of Apellis Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Apellis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Apellis Pharmaceuticals' public news can be used to forecast risks associated with investment in Apellis. The trend in average sentiment can be used to explain how an investor holding Apellis can time the market purely based on public headlines and social activities around Apellis Pharmaceuticals. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Apellis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Apellis Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Apellis Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Apellis Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Apellis Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Apellis Pharmaceuticals' short interest history, or implied volatility extrapolated from Apellis Pharmaceuticals options trading.

Pair Trading with Apellis Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Apellis Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Apellis Pharmaceuticals

-0.73APAApa Corp Potential GrowthPairCorr
-0.7JPMJP Morgan Chase Fiscal Year End 13th of January 2023 PairCorr
-0.69LENLennar Corp Fiscal Year End 21st of December 2022 PairCorr
-0.64GEOGeo Group TrendingPairCorr
The ability to find closely correlated positions to Apellis Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Apellis Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Apellis Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Apellis Pharmaceuticals to buy it.
The correlation of Apellis Pharmaceuticals is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Apellis Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Apellis Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Apellis Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Apellis Pharmaceuticals Altman Z Score, Apellis Pharmaceuticals Correlation, Apellis Pharmaceuticals Valuation, as well as analyze Apellis Pharmaceuticals Alpha and Beta and Apellis Pharmaceuticals Hype Analysis. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for analysis

When running Apellis Pharmaceuticals price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Is Apellis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.5 B
Quarterly Revenue Growth YOY
2.9
Return On Assets
(0.46) 
Return On Equity
(5.07) 
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Apellis Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.